$APTO, $CDMO, $ENDP, $IGMS, $ILMN

Here are some of the many biotech and pharma stocks that have been given big Northside targets for Y 2020 by Key sector analysts, as follows:

Aptose Biosciences Inc. (NASDAQ:APTO) was started with a new Buy rating and a 10 price target at Piper Jaffray on 9 January. This represented well over 80% in implied upside from the prior 5.32 closing price, but shares initially rose 8% to 7.75 after the call. The 52-wk trading range is 1.576 – 6.04, and the shares had been above the Aptose closed on a $74-M capital raise at 4.00/share via a stock sale in December.

Avid Bioservices Inc. (NASDAQ:CDMO) was reiterated as Buy with a 10 price target at Janney on 6 January. The latest price was 6.95, implying 44% upside if its analysis is correct. Janney is seeing an increased strategic value in Y 2020 as a pure-play monoclonal producer that is still a small-cap stock competing with larger companies at a time when the global capacity for biologics manufacturing remains constrained. The firm also sees an inflection point to faster growth and profitability coming in Y 2020.

Endo International PLC (NASDAQ:ENDP) was upgraded to Overweight from Neutral and its target price was raised to 7 from 5 at Piper Jaffray on 3 January. Endo recently traded at 4.60, implying more than 52% upside if the firm is correct. It is a $1-B market cap company that recently launched a generic version of Afinitor tablets in the United States via its Par Pharma unit. The company’s news release from December indicated that the name brand drug saw approximately $412-M in sales over the past Quarters.

IGM Biosciences Inc. (NASDAQ:IGMS), a $1-B market cap company that is into research and development of engineered therapeutic engineered Immunoglobulin M (IgM) antibodies, was reiterated as Overweight at Piper Jaffray on 6 January. What stood out here was that the 26 target price was raised to 53. That represents about 60% upside from the recent 32.42 share price. The 52-wk trading range is 16.10 – 57.42.

Illumina Inc. (NASDAQ:ILMN), which is the leader in gene sequencing and genomics, was started as Buy with a 385 target price in a new sector call at Citigroup. Shares recently traded at 322.15, for an implied upside of 17% if the Citigroup call is correct. This was 1 of the more Bullish targets in that sector call, and some of the peer companies were viewed as Hold/Neutral positions rather than with big Buy ratings and big implied upside. On 9 January, Piper Jaffray reiterated its Overweight rating and raised its target price to 370 from 340.

Have a terrific week

  APTO, biopharmas, Bullish, buy, CDMO, development, ENDP, growth, IGMS, ILMN, northside, pharma, potential, price, profitability, research, target

The following two tabs change content below.

• Bio
• Latest Posts

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Latest posts by Paul Ebeling (see all)

• Goldie Says Stocks Can Go Higher - January 23, 2020
• Wall Street’s Key Stock Analysts Research Reports - January 23, 2020
• 2020: Rolex 24 Ready to Kick Off Racing Season - January 23, 2020